System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Mar Llamas-Velasco is an expert in Dermatology at Hospital Universitario de La Princesa (Spain). As of October 2026, ScienceLeadR ranks Mar Llamas-Velasco in the top 1% of experts worldwide for Psoriasis and Skin Diseases, Papulosquamous. Mar Llamas-Velasco has authored 279 publications, the most recent in 2026, and is an investigator in 5 clinical trials, 1 of them ongoing. SLR score: 883 (community average: 125). How the SLR is computed.

LeadR Profile

Mar Llamas-Velasco Hospital Universitario de La Princesa Spain
883 ScienceLeadR Reputation 883

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Public Health - Immunology - Infectiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2007 - 2026
Source: PubMed

Hospital Universitario de La Princesa

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 279

Citations

Citations: 4 592 1st author: 95 Last author: 31 Unique author: 2

Main journals

Actas Dermosifiliogr 30
J Cutan Pathol 30
J Eur Acad Dermatol Venereol 25
Am J Dermatopathol 22
J Am Acad Dermatol 15

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Distinct Gut Microbiota Signatures are Associated With Progression of Atherosclerosis in Patients With Psoriasis: Results From the EDSAP Study.
PMID 42870427 — syphilis, atherosclerosis, psoriasis, gastrointestinal microbiome, microbiota		Br J Dermatol20260
Monoclonal gammopathy of dermatological significance: non-amyloid paraprotein deposits with light and heavy chains.
PMID 42383415 — paraproteins, skin diseases, amyloid		J Dtsch Dermatol Ges20260
Integrative skin-blood transcriptomic analysis identifies circulating biomarkers reflecting disease activity in atopic dermatitis.
PMID 42344215 — skin, genes, blood, serum, dermatitis, biomarkers, dermatitis, atopic		Front Allergy20260
Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS).
PMID 42200950 — safety, aged, biological therapy, psoriasis		Pharmacy (Basel)20260
Safety Profile of Systemic Therapy for the Management of Psoriasis in Patients With Diabetes Mellitus: Data From the BIOBADADERM Prospective Cohort.
PMID 42177023 — diabetes mellitus, sexually transmitted diseases, safety, incidence, cyclosporine, therapeutics, psoriasis, acitretin, dermatology		Actas Dermosifiliogr20260

Clinical Studies 5

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 2
Phase 4 2
Phase 2 1

By status:

Completed 2
Terminated 2
Active not recruiting 1

By type:

Interventional 5

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 5

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 3 Multicenter Randomized Double blind Placebo controlled and Deucravacitinib Active Comparator controlled Study to Evaluate the Efficacy and Safety of JNJ 77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
2023-505121-14-00 — safety, therapeutics, psoriasis		Phase 3Active not recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS